MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bertaso, F.
Right arrow Articles by Dolphin, A. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bertaso, F.
Right arrow Articles by Dolphin, A. C.

Vol. 63, Issue 4, 832-843, April 2003


Mechanism of Action of Gq to Inhibit Gbeta gamma Modulation of CaV2.2 Calcium Channels: Probed by the Use of Receptor-Galpha Tandems

Federica Bertaso, Richard J. Ward, Patricia Viard, Graeme Milligan, and Annette C. Dolphin

Department of Pharmacology, University College London, London, United Kingdom (F.B., P.V., A.C.D.); and Molecular Pharmacology Group, Division of Biochemistry and Molecular Biology, Institute of Biomedical and Life Sciences, University of Glasgow, Glasgow, United Kingdom (R.J.W., G.M.)

    Abstract
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References

The stable interaction of a G-protein coupled receptor and a particular partner G-protein was made possible by creating tandems between the alpha 2A adrenergic receptor (alpha 2A-R) and pertussis toxin-resistant mutants of different Galpha subunits of heterotrimeric G-proteins. Both alpha 2A-R-Galpha o and alpha 2A-R-Galpha i proved able to reconstitute agonist-induced voltage-dependent inhibition of N-type calcium channels (CaV2.2) similar to the wild-type alpha 2A-R when expressed in COS-7 cells. The interaction of Gq with the Gi/o signaling pathways was studied by expressing either Galpha q or a chimeric construct based on Galpha q containing the last five amino acids of Galpha z, which is activated by alpha 2A-R. It was found that Galpha qz5 activated by the wild-type alpha 2A-R inhibited CaV2.2 currents in a voltage-independent fashion. Furthermore, Galpha qz5 counteracted the voltage-dependent inhibition resulting from alpha 2A-R-Galpha o activation. We subsequently investigated the basis for the behavior of Galpha qz5. Our evidence suggests that this occurs as a result of a downstream effect of activation of Galpha qz5 because it was blocked by C-terminal construct of phospholipase Cbeta 1. Furthermore it is likely to occur in part via protein kinase C (PKC) activation, because the PKC activator phorbol dibutyrate mimicked the effects of Galpha qz5 in alpha 2A-R-Galpha o-transfected cells. Conversely, cells expressing both alpha 2A-R-Galpha o and Galpha qz5 exhibited a partial restoration of voltage-dependent inhibition in the presence of the PKC inhibitor bisindolylmaleimide I (GF 109203X). The potential sites of phosphorylation are discussed.

    Introduction
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References

Calcium influx in any cell requires fine tuning to guarantee the correct balance between activation of calcium-dependent processes, such as muscle contraction and neurotransmitter release, and calcium-induced cell damage. G-protein-coupled receptors (GPCRs) play a role in negative feedback of the activity of voltage-dependent calcium channels (Dolphin, 1995). Establishing the basis for the specificity of the relationships between membrane receptors, G-proteins, and effectors has proven elusive, in part because of the promiscuity of the partners involved when expressed in heterologous systems. When different G-protein subunits are over-expressed together with GPCRs and calcium channels, the degree of specificity is rather low. For example, the alpha 2A-adrenergic receptor (alpha 2A-R) couples to all members of the Gi/o family, including the pertussis toxin (PTX)-sensitive Go and Gi, and the PTX-insensitive Gz (for review, see Hille, 1994).

In native systems, however, receptors display a more selective activation of endogenous G-proteins subtypes, with Go being more important than Gi in the inhibition of calcium currents in sensory neurons (Campbell et al., 1993). Furthermore, in sympathetic neurons, muscarinic activation of G-protein-activated inward-rectifier (GIRK) channels is mediated by Gi, whereas muscarinic inhibition of N-type calcium channels is mediated by GoA (Fernández-Fernández et al., 2001). These results point to the importance of the cellular localization of each receptor and G-protein subtype.

For GPCRs that associate with PTX-sensitive G-proteins, production of Gbeta gamma dimers seems to be responsible for the direct voltage-dependent inhibition of N- and P/Q-type channels (Herlitze et al., 1996; Stephens et al., 1998), although it has also been proposed that in chick sensory neurons, Gbeta gamma results in activation of PKC, to mediate the voltage-dependent inhibition caused by norepinephrine (Diversé-Pierluissi et al., 1995). Furthermore, Galpha subunits have also been implicated in mediating G-protein modulation (Diversé-Pierluissi et al., 1995).

One way to identify the direct effects of a specific G-protein on calcium channel activity is to link the G-protein alpha  subunit to the receptor of choice to form a tandem construct. One of the advantages of this approach is the elimination of one of the signal amplification steps, occurring at the receptor/G-protein interaction level, because the two components are constrained to work with a 1:1 stoichiometry. Furthermore, there is increasing evidence against the established model which sees G-proteins shuttling between receptor and effector, and toward a view that there is a close localization of signal transduction elements in distinct membrane domains (Seifert et al., 1999). We used fusion proteins between the alpha 2A-R and either Galpha i1 or Galpha o1, both of which were rendered PTX-insensitive by means of a point mutation at residue 351 (Bahia et al., 1998). The Ile351 Galpha mutants were chosen over other possible PTX-resistant mutants because they resulted in the strongest activation by alpha 2A-R (Bahia et al., 1998). Activation of these tandems by the alpha 2A-R agonist clonidine was studied in COS-7 cells coexpressing N-type channels (CaV2.2) and comparing the response to that produced by the activation of the wild-type alpha 2A-R. These tandems have been found able to interact with endogenous G-proteins to a certain extent (Burt et al., 1998). In the present study, treatment of cells with PTX before recording allowed the receptor/G-protein tandems to be studied in isolation, effectively removing the contribution of endogenous Gi/o proteins.

The carboxyl terminus of the Galpha subunit is not only a determinant of its sensitivity to PTX-dependent ADP-ribosylation but is also essential to confer specificity of coupling to GPCRs (Conklin et al., 1993). To examine whether Gbeta gamma dimers liberated from Gq could also inhibit N-type Ca2+ channels, we exploited a chimeric Galpha q-protein. This construct was formed by a Galpha q subunit in which the last 5 amino acids were substituted for the corresponding amino acids from Galpha z. The resulting Galpha qz5, unlike Gq itself, is able both to couple to the alpha 2A-R and to activate effectors specific to the Gq family, such as phospholipase C and the downstream protein kinase C (PKC) (Conklin et al., 1996). We report the effects of such a construct in isolation and when coexpressed with the alpha 2A-R-Galpha o fusion protein and compare these effects with those of the wild type Gq subunit. The involvement of downstream effectors of Galpha qz5 is also examined.

    Materials and Methods
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References

Constructs. COS-7 cells were transiently transfected with the following cDNAs: rabbit CaV2.2 (GenBank accession no. D14157); rat beta 1b (GenBank accession no. X11394); and mut-3 green fluorescent protein (GFP).

The PTX-resistant alpha 2A-R-G-protein fusion proteins used throughout this study were prepared as described previously (Cavalli et al., 2000). In brief, Cys351 of rat Galpha i1 and Galpha o1 was mutated to Ile by site-directed mutagenesis and then used to create the alpha 2A-R-Galpha fusion proteins using porcine alpha 2A-R in pcDNA3. The Ile19Ala, Glu20Ala (IE) mutant of Galpha o1 was constructed, based on studies of an equivalent mutation (Ile25Ala, Glu26Ala) of Galpha q (Evanko et al., 2000), and this was then incorporated into the PTX-resistant alpha 2A-R-Galpha o fusion protein. The wild-type Galpha q subunit (Galpha q w.t.) and the Galpha qz5 subunits described previously (Conklin et al., 1993) were subcloned into pMT2. Galpha -transducin (Galpha t) was in pcDNA3. The pEGFP-PLC-beta 1ct fusion construct of the C terminus of phospholipase Cbeta (PLC-beta 1ct) was described previously (Kammermeier and Ikeda, 1999).

Cell Culture and Transfections. Cells were cultured in Dulbecco's modified Eagle's medium supplemented with 10% newborn calf serum, penicillin (100 IU/ml) and streptomycin (100 µg/ml) (all from Invitrogen, Paisley, UK) at 37°C, 5% CO2, and passaged every 3 to 4 days. For transient transfections of the different constructs, a cDNA mixture was made containing the voltage-dependent calcium channel CaV2.2 subunit cDNA in a ratio of 3:1 with all the other constructs, beta 1b, alpha 2A-R, alpha 2A-R-G-protein tandems, and/or the Galpha subunits. Mut-3 GFP cDNA was also included at a ratio of 0.2. For transfection, 10 µl of GenePORTER reagent (Qbiogene, Harefield, UK) and 2 µl of cDNA mixture were preincubated in 1 ml of Dulbecco's modified Eagle's medium at 20°C for 1 h before addition to 35-mm Petri dishes containing approximately 2 × 106 cells. Cells were cultured at 37°C for 72 h, replated using a nonenzymatic cell dissociation medium (Sigma, Poole, UK), and maintained at 27°C for 1 to 8 h, before recording. PTX (Sigma) was used to inactivate the endogenous Galpha i/o subunits by adding it to the culture medium at a concentration of 40 to 100 ng/ml for 16 h before replating the cells.

[3H]RS-79948-197 Binding. To determine the levels of expression of the various alpha 2A-R-G-protein fusion proteins, the specific binding of [3H]RS-79948-197 was measured as described previously (Ward and Milligan, 2002).

[35S]GTPgamma S Binding. [35S]GTPgamma S binding experiments were performed essentially as described for receptor-G-protein tandems incorporating Galpha 11 (Carrillo et al., 2002). These were initiated by the addition of membranes containing 50 fmol of the fusion constructs to an assay buffer [20 mM HEPES, pH 7.4, 3 mM MgCl2, 100 mM NaCl, 1 µM guanosine 5'-diphosphate, 0.2 mM ascorbic acid, and 50 nCi of [35S]GTPgamma S] in the absence or presence of clonidine (10 µM). Nonspecific binding was determined in the same conditions but in the presence of 100 µM GTPgamma S. Reactions were incubated for 15 min at 30°C and were terminated by the addition of 0.5 ml of ice-cold buffer containing 20 mM HEPES, pH 7.4, 3 mM MgCl2, and 100 mM NaCl. The samples were centrifuged at 16,000g for 15 min at 4°C, and the resulting pellets were resuspended in solubilization buffer (100 mM Tris, 200 mM NaCl, 1 mM EDTA, and 1.25% Nonidet P-40) plus 0.2% SDS. Because all the alpha 2A-R-G-protein tandems used in these studies incorporated a hemagglutinin (HA) epitope tag at the N terminus of the receptor, samples were precleared with Pansorbin (Calbiochem, Nottingham, UK), followed by immunoprecipitation with the anti-HA antiserum 12CA5 (Roche Diagnostics, Lewes, UK). Finally, the immunocomplexes were washed twice with solubilization buffer, and bound [35S]GTPgamma S was measured by liquid scintillation counting.

Immunoprecipitation and Immunodetection Studies. To analyze the interaction of alpha 2A-R-Galpha o with Gbeta gamma dimers, cells were transfected with alpha 2A-R-Galpha o or alpha 2A-R-Ile19Ala, Glu20Ala Galpha o in the absence or presence of plasmids encoding G-protein beta 1 and gamma 2 subunits. Cells were washed once with ice-cold phosphate-buffered saline and immediately homogenized in a lysis medium containing 50 mM HEPES, pH 7.4, 10 mM Na4P2O7, 100 mM NaF, 10 mM EDTA, 0.1 mM Na3VO4, 1% Triton X-100, and a protease inhibitor cocktail (Complete; Roche). Cell lysates were centrifuged (15 min, 13,000 rpm) and the supernatants precleared for 1 h with nonspecific serum and protein A. Next, samples were incubated overnight with a polyclonal antiserum directed against the C-terminal decapeptide of Galpha o1 (Mullaney and Milligan, 1990). The immunocomplexes were then captured with protein A-agarose.

For immmunoblotting, cell lysates or immunoprecipitates were subjected to SDS-polyacrylamide gel electrophoresis (PAGE). Proteins were transferred to polyvinylidene fluoride (PVDF) membranes and blocked for 2 h with 5% nonfat dried milk in 0.05% Tween 20/Tris-buffered saline (TTBS). Then, the PVDF membranes were probed overnight at 4°C with an antiserum (BN) directed against the N-terminal decapeptide of the G-protein beta 1 subunit (Green et al., 1990) and washed with TTBS. The PVDF membranes were incubated for 20 min with horseradish peroxidase conjugated to anti-rabbit IgG (1:20,000) (Amersham Biosciences). Finally, they were washed with TTBS and developed by enhanced chemiluminescence.

Electrophysiology. Fluorescent COS-7 cells expressing GFP were chosen for whole-cell, patch-clamp recording. Borosilicate glass electrodes were used with a resistance of 2 to 5 MOmega when filled with a solution containing 140 mM cesium aspartate, 5 mM EGTA, 2 mM MgCl2, 0.1 mM CaCl2, 2 mM K2ATP, and 20 mM HEPES, pH adjusted to 7.2 with CsOH, 310 mOsM with sucrose. Cells were perfused with an extracellular solution containing 160 mM tetraethylammonium-Br, 2 mM KCl, 1.0 NaHCO3, 1.0 MgCl2, 10 mM HEPES, 4 mM glucose, and 10 mM BaCl2, pH 7.4, 320 mOsM with sucrose. Barium currents were recorded using an Axopatch-1D amplifier (Axon Instruments, Union City, CA). Data were filtered at 2 kHz, digitized at 5 to 10 kHz, and analyzed using pCLAMP 6 (Axon Instruments) and Origin 5.0 (Microcal, Northampton, MA). Cell capacitance compensation and series resistance compensation between 65 and 80% were applied electronically. Records are shown after leak subtraction (P/4 or P/8 protocol).

Facilitation was assessed by using a double-pulse protocol (see Fig. 1a, top). A first 30-ms step (P1) usually to 0 mV was followed by a 300-ms period of repolarization to -100 mV. A strongly depolarizing prepulse PP of 30 to +100 mV was then delivered before a second pulse (P2) to the same voltage as the first test pulse, to assess the voltage-dependence of current inhibition. The PP and the second pulse were separated by a 10-ms repolarization time to -100 mV. Pulses were delivered every 15 s. Currents were measured 10 ms after the onset of both P1 and P2 and the average over a 2-ms period was calculated and used for subsequent analysis. The 300-ms interval between P1 and PP was sufficient to minimize the voltage-dependent calcium channel inactivation caused by P1. The duration and amplitude of the PP were chosen to produce maximal facilitation in the conditions used (data not shown). Experiments were performed at room temperature (20-24°C). Drugs were applied by the use of a gravity-fed, electronically controlled, multibarrelled perfusion system. Current density-voltage (I-V) relationships were fitted with a modified Boltzmann equation as follows: I = Gmax (V - Vrev)/(1 + exp(-(V - V50,act)/k)), where I is the current density (picoamperes per picofarad), Gmax is the maximal conductance (nanosiemens per picofarad), Vrev is the reversal potential, V50,act is the mid-point voltage for current activation, and k is the slope factor.


View larger version (27K):
[in this window]
[in a new window]
 
Fig. 1.   Comparison of inhibition of IBa by alpha 2A-R and alpha 2A-R-Gi/o tandems. Top, double-pulse voltage-clamp protocol used to measure the PP facilitation of IBa. Two 30-ms test pulses (P1 and P2) to 0 mV were separated by 300-ms repolarization to -100 mV, a 50-ms PP to +100 mV and a 10-ms period of repolarization to -100 mV. Recordings were made every 15 s. a-d, schematic representation of the alpha 2A-R constructs is given on the left. Example recording from cells expressing different receptor constructs. Currents recorded in control and after application of 10 µM clonidine are superimposed. a, the alpha 2A-R w.t.; b, the PTX-resistant alpha 2A-R-Galpha o; c, the PTX-resistant alpha 2A-R-Galpha i; d, example traces after preincubation with PTX from a cell expressing alpha 2A-R w.t.; e, summary of IBa inhibition by clonidine before (P1, ) and after (P2, ) the depolarizing PP. Values are reported without and with pretreatment with PTX for the alpha 2A-R w.t. (n = 4 and 9, respectively), and for the receptor tandems alpha 2A-R-Galpha o (n = 5 and 18, respectively) and alpha 2A-R-Galpha i (n = 8 for both) (*, p < 0.05; **, p < 0.01; either paired t test, between P1 and P2, or unpaired t test between ± PTX, as indicated).

The time constant of activation (tau act) was calculated by fitting a single exponential to the current traces: I = A × exp(-t/tau act) + C, where A is the amplitude of the component with time constant tau , and C is a constant. Data are expressed as mean ± S.E.M., and statistical significance between conditions was examined using Student's t test or paired t test, as appropriate.

Materials. [3H]RS-79948-197 (90 Ci/mmol) was from Amersham Biosciences (Little Chalfont, Buckinghamshire, UK), [35S]GTPgamma S (1250 Ci/mmol) was from PerkinElmer Biosciences (Warrington, UK). Clonidine hydrochloride (Calbiochem) was prepared as a 10-2 M stock in H2O. The protein kinase C activator phorbol-12,13-dibutyrate (PDBu; Calbiochem) and the PKC inhibitor bisindolylmaleimide I (GF 109203X, Calbiochem) were prepared as 10-2 M stock in DMSO. All drugs were diluted in the experimental solutions to the final concentrations indicated.

    Results
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References

Effect of the alpha 2A Adrenergic Receptor-Galpha i and -Galpha o Tandems. We first expressed either alpha 2A-R w.t. or the PTX-insensitive receptor-Galpha tandems alpha 2A-R-Galpha o1C351I (alpha 2A-R-Galpha o) or alpha 2A-R-Galpha iC351I (alpha 2A-R-Galpha i) together with the CaV2.2 calcium channel. The inhibition of the expressed Ba2+ currents (IBa) by activation of the alpha 2A-R w.t. was compared with the effect of the receptor G-protein tandems (Fig. 1). Overall, the alpha 2A-R agonist clonidine (10 µM) inhibited N-type IBa via activation of both the free alpha 2A-R and the tandem alpha 2A-R-Galpha constructs, as exemplified by the current traces in Fig. 1, a-c. The inhibition was rapid (< 15 s) and reversible upon washing (data not shown). The extent of IBa inhibition at 0 mV is given in Fig. 1e (). In the absence of PTX, IBa was similarly reduced by both the wild-type alpha 2A-R (64.2 ± 6.6%, n = 9, Fig. 1a) and the tandems alpha 2A-R-Galpha o (77.6 ± 6.6%, n = 5, Fig. 1b) and alpha 2A-R-Galpha i (64.1 ± 4.0%, n = 8, Fig. 1c). Thus, removal of the amplification step between receptor and G-protein did not affect the ability of Gi/o to produce inhibition of CaV2.2 IBa.

It has been observed previously that chimeric receptor-Galpha constructs are able to activate not only the tethered Galpha subunit but also endogenous subunits of the Gi/o family (Burt et al., 1998). The use of PTX therefore allows isolation of the effects of exogenous Galpha subunits mutated to be PTX-resistant by rendering the endogenous Gi/o subunits unable to couple to the receptor. Preincubation of the cells with PTX greatly reduced the inhibition produced by the alpha 2A-R w.t. (see traces in Fig. 1d and mean results in Fig. 1e). Conversely, PTX did not significantly affect the functioning of the two PTX-insensitive receptor G-protein tandems. The calcium channel currents at 0 mV were still reduced by 74.1 ± 6.5% (n = 18, Fig. 1b) and 62.9 ± 9.1% (n = 8, Fig. 1c) with the Galpha o and the Galpha i fusion proteins, respectively, after pretreatment with the toxin (Fig. 1e). Experiments repeated with a lower concentration of clonidine (100 nM) gave comparable results in terms of degree of inhibition, demonstrating that maximal receptor activation was achieved at the concentration of agonist used (data not shown).

Inhibition of N-type currents by the receptor-Galpha i/o tandems was largely voltage-dependent, as seen by using a double pulse voltage-clamp protocol (Fig. 1, a----d). The PP was able to reverse the agonist-induced inhibition induced by either alpha 2A-R w.t. (Fig. 1a) or the alpha 2A-R-Galpha o (Fig. 1b) and alpha 2A-R-Galpha i (Fig. 1c) tandems, whereas incubation with PTX eliminated the voltage-dependent effects of the alpha 2A-R w.t. (Fig. 1d). The amount of inhibition by clonidine before and after the PP is summarized in Fig. 1e. The resultant "facilitation" (determined as the P2 current amplitude divided by P1 current amplitude) was substantial for all three receptor constructs. In all cases, however, removal of inhibition during P2 by the PP to +100 mV was never complete, indicating a voltage-independent inhibitory component.

As a corollary of the voltage-dependence of the inhibition of IBa by clonidine, it should also be abolished at large step potentials. The voltage-clamp protocol used to examine this was similar to that shown in Fig. 1 with the exception that both test pulses (P1 and P2) were varied from -40 to +70 mV in 10-mV increments. Example traces are shown in Fig. 2a, whereas the mean I-V plots for values measured in P1, before and during application of clonidine, for cells expressing the alpha 2A-R-Galpha o (n = 8) are shown in Fig. 2b. With all receptor constructs, the agonist caused both a reduction in IBa and a depolarizing shift in the I-V relationship. The V50,act during P1 was significantly depolarized for cells expressing alpha 2A-R-Galpha o, from -6.4 ± 3.1 to +9.0 ± 4.0 mV (p < 0.05, n = 6, Fig. 2b) and, for cells expressing alpha 2A-R-Galpha i, from +2.5 ± 2.4 to +9.7 ± 0.7 mV (p < 0.05, n = 6). No significant differences in the Vrev or in the Gmax were detected (Fig. 2b; data not shown). The P2/P1 facilitation ratios for the different test potentials are reported in Fig. 2, c-d. The PP revealed some tonic facilitation in the absence of the agonist (), which was more marked when expressing the alpha 2A-R w.t., where P2/P1 was 2.3 ± 0.3 at 0 mV (Fig. 2c). Clonidine enhanced the voltage-dependent facilitation, although the effects were much greater for the alpha 2A-R-Galpha o tandem than for the alpha 2A-R w.t. (Fig. 2d). Maximal facilitation was obtained at -10 or 0 mV and it was absent above +20 mV.


View larger version (31K):
[in this window]
[in a new window]
 
Fig. 2.   Effect of varying the test potential on IBa inhibition by receptor-Gi/o tandems. a, top, voltage-clamp protocol. Both P1 and P2 were varied from -40 to +70 mV in 10 mV increments. Bottom, an example of superimposed traces recorded in the presence of clonidine from a cell expressing alpha 2A-R-Galpha o and treated with PTX. b, I-V relationship for cells expressing alpha 2A-R-Galpha o before the PP. The data are average values of current density before (open circle ) and after () application of clonidine (n = 8). I-V plots were fitted with a modified Boltzmann equation (see Materials and Methods). c and d, values of IBa facilitation ratios (P2/P1) in control () and in the presence of clonidine (black-square), for the alpha 2A-R w.t. in the absence of PTX (n = 4) (c) and alpha 2A-R-Galpha o treated with PTX (n = 8) (d). Only the values for voltages between -10 and +40 mV are reported. Statistical significances of the effect of clonidine: *, p < 0.05; **, p < 0.01, paired t test.

Not only did activation of the alpha 2A-R-Galpha tandems cause a reduction in current amplitude but the activation phase of the current was typically slowed during P1; this effect was reversed by the PP (e.g., Fig. 1, a-c). For example, for those cells transfected with the alpha 2A-R-Galpha o tandem, the tau act at 0 mV during P1 was 3.7 ± 0.5 ms in control and 6.1 ± 1.1 ms during clonidine application (n = 10, p < 0.05, see Fig. 1b). This slowed activation was reversed by Galpha t, which acts as a Gbeta gamma sink to sequester free Gbeta gamma subunits but does not couple to the alpha 2A-R. Example traces are shown in Fig. 3a (top). After cotransfection of Galpha t with alpha 2A-R-Galpha o, there was no longer a difference in the tau act values measured in control and clonidine during P1 (2.9 ± 0.6 ms and 3.4 ± 0.5 ms, respectively, n = 9). Along with this effect, Galpha t was able significantly to reduce inhibition by clonidine at 0 mV from 74.1 ± 6.5 to 43.0 ± 6.7% (p < 0.001; Fig. 3b) and to reduce the P2/P1 facilitation ratio in the presence of clonidine to 1.54 ± 0.24 at 0 mV, although this was still significantly greater than the P2/P1 ratio under control conditions (Fig. 3c).


View larger version (26K):
[in this window]
[in a new window]
 
Fig. 3.   The effects of alpha 2A-R-Galpha o are mediated by Gbeta gamma . A, example traces recorded in cells expressing the alpha 2A-R-Galpha o tandem and Galpha t (upper traces) or the IE mutant of alpha 2A-R-Galpha o (lower traces). b, inhibition by clonidine in cells expressing alpha 2A-R-Galpha o alone (n = 10), alpha 2A-R-Galpha o, and Galpha t (n = 9) or the IE mutant of alpha 2A-R-Galpha o (n = 3). Statistical significance, ***, p < 0.001 compared with control, Student's t test. c, facilitation ratios for the same cells as in b. Statistical significance, **, p < 0.01 compared with control, paired t test. d, mutation of Ile19 and Glu20 of Galpha o inhibits interaction with the G-protein beta 1 subunit. Cells were mock transfected (lane 1) or transfected with either the alpha 2A-R-Galpha o fusion protein (lanes 2, 4) or the alpha 2A-R-(Ile19Ala, Glu20Ala)-Galpha o fusion (IE mutant, lanes 3 and 5). In lanes 2 and 3, cells were also transfected with plasmids encoding Gbeta 1and Ggamma 2. Top, samples were immunoprecipitated with antiserum OC against the C-terminal of Galpha o1, resolved by SDS-PAGE, and immunoblotted with an antiserum against the Gbeta 1 subunit. Bottom, lysates from the cells were resolved by SDS-PAGE and immunoblotted to detect expression of the beta 1subunit. Data are from a representative experiment.

Given that these data were obtained in the presence of PTX, to prevent promiscuous coupling of the tandems to additional endogenous Gi/o proteins, these findings indicate that the alpha 2A-R tandems are able to reconstitute inhibitory effects on CaV2.2 calcium channel currents by means of the tethered Galpha i/o that are almost identical to the wild-type receptor coupling to endogenous G-proteins and that such effects are very likely to be mediated purely by Gbeta gamma dimers. It has been found previously that mutation of both Ile25 and Glu26 of Gqalpha to Ala severely limits interaction with the Gbeta gamma complex (Evanko et al., 2000). These residues are highly conserved in other G-protein alpha  subunits. We thus constructed a form of the PTX-resistant alpha 2A-R-Galpha o tandem (IE) that also incorporated the equivalent mutations of Ile19Ala and Glu20Ala in Galpha o. Application of clonidine to cells expressing the IE form of the alpha 2A-R-Galpha o tandem produced no inhibition of IBa, and no effect on facilitation (Fig. 3, a, bottom, and b-c). It is also evident that these CaV2.2 currents show some tonic modulation, being slowly activating and facilitated by a prepulse, although this is no greater than for the free alpha 2A-R (Fig. 2c).

To examine the binding of Gbeta gamma to the IE mutant of alpha 2A-R-Galpha o, either alpha 2A-R-Galpha o or the IE form of this construct was cotransfected together with plasmids encoding the Gbeta 1 and Ggamma 2 subunits. Cell lysates were subsequently immunoprecipitated with an antiserum (OC) that identifies the C-terminal decapeptide of Galpha o1. Such samples were then resolved by SDS-PAGE, transferred to PVDF membranes, and immunoblotted with an antiserum (BN) that identifies the N-terminal decapeptide of Gbeta 1. Although the alpha 2A-R-Galpha o tandem allowed coimmunoprecipitation of beta 1 subunit (Fig. 3d, lane 2), this was not observed for the IE form of the tandem receptor (Fig. 3d, lane 3).

Investigation of alpha 2A-R-Galpha q and alpha 2A-R-Galpha qz5 Chimeras. Because the expression of the receptor/G-protein tandems indicated that the release of activated Galpha subunits, Galpha i and Galpha o, does not play any direct role in G-protein-effector coupling for calcium channel inhibition, we were interested in studying whether Gbeta gamma released from another class of G-protein, Gq, could also participate in the inhibitory process. However Gq is known not to couple efficiently to the alpha 2A-R (Dorn et al., 1997). To use the same receptor for activation of both Gi/o and Gq pathways, we therefore employed the chimeric construct Galpha qz5. This subunit conserved the main structure of Galpha q but the last five amino acids were substituted for those of Galpha z, a PTX-resistant member of the Gi/o family that does couple to the alpha 2A-R (Conklin et al., 1993). Tandem alpha 2A-R-Galpha q and alpha 2A-R-Galpha qz5 constructs were assembled, and their functionality was assessed biochemically.

Evidence of the activation of the PTX-resistant G-proteins within the alpha 2A-R-Galpha tandems by clonidine was obtained by monitoring agonist-induced binding of [35S]GTPgamma S. Expression levels of the alpha 2A-R-containing fusion proteins in membranes of PTX-treated cells were quantified by saturation ligand binding studies employing the high-affinity alpha 2-adrenoceptor antagonist [3H]RS-79948-197. [35S]GTPgamma S binding studies were performed in the presence and absence of clonidine (10 µM) on membrane fractions expressing equal amounts of the various fusion proteins. After this, the anti-HA antibody 12CA5 was used to immunoprecipitate the samples, because all of these constructs contained an N-terminal HA epitope tag. Significant levels of [35S]GTPgamma S binding were observed for both the Galpha o- and Galpha i-containing fusion proteins; this was stimulated markedly by the presence of clonidine (Fig. 4). In contrast, little binding of [35S]GTPgamma S was observed to the alpha 2A-R-Galpha q and alpha 2A-R-Galpha qz5 constructs, even in the presence of clonidine, consistent with a lack of activation of these G-proteins by the associated alpha 2A-R. The inability of clonidine to promote binding of [35S]GTPgamma S to the fusion proteins containing Galpha q does not reflect the well appreciated difficulty in monitoring nucleotide exchange for such G-proteins in standard [35S]GTPgamma S binding assays. We have recently shown that combination of use of receptor-G-protein tandems and selective immunoprecipitation allows a 30-fold stimulation of binding in the presence of agonist when such G-proteins are linked in tandem with appropriate receptors (Carrillo et al., 2002). A preliminary investigation also failed to show any clonidine-mediated inhibition of CaV2.2 via the alpha 2A-R-Galpha qz5 tandem, but because these receptor-Galpha q tandems were nonfunctional biochemically, their coupling to CaV2.2 was not further examined.


View larger version (26K):
[in this window]
[in a new window]
 
Fig. 4.   Clonidine stimulates binding of [35S]GTPgamma S to fusion proteins between the alpha 2A-R and both Galpha o1 and Galpha i1. Membranes were prepared from cells transfected to express fusion proteins between an N-terminally HA-tagged form of the alpha 2A-R and each of (Cys351Ile) Galpha o, (Cys351Ile) Galpha i, Galpha q, or Galpha qz5. After [35S]GTPgamma S binding assays performed in the absence () or presence () of clonidine (10 µM), samples were immunoprecipitated with the anti-HA antibody 12CA5 and 35S content was determined. Data represent mean ± S.E.M. (n = 3).

We therefore employed free Galpha q and Galpha qz5 to examine whether Gbeta gamma released from Gq or Gqz5 can signal to N-type calcium channels (Fig. 5a). We confirmed, by coexpressing the alpha 2A-R w.t. with Galpha q w.t. in cells treated with PTX, that Galpha q did not couple directly to the alpha 2A-R. Perfusion of clonidine induced only 7.1 ± 1.1% reduction in the current (n = 5, Fig. 5b). In contrast, expression of Galpha qz5 with the alpha 2A-R w.t. resulted in significantly greater inhibition of CaV2.2 currents by clonidine (35.8 ± 8.6%, n = 9, Fig. 5, a and b). Surprisingly however, this was not removed by a PP to +100 mV, the inhibition in P2 being 34.5 ± 5.4% (n = 9, Fig. 5b). Thus, the inhibition elicited by Galpha qz5 was much greater than that elicited by Galpha q w.t. (p < 0.001) but was not voltage-dependent. The P2/P1 facilitation ratio in the presence of Galpha qz5 was around unity and was unaffected by the presence of agonist (0.98 ± 0.07 in control, 1.20 ± 0.23 in clonidine, p > 0.05, Fig. 5c). Current traces in the presence of Galpha qz5 showed no evidence of slowing of the kinetics of activation in response to clonidine (e.g., traces in Fig. 5a and data not shown). To determine whether voltage-dependent inhibition was completely absent for Galpha qz5, we also examined the voltage-dependence of inhibition over a range of potentials. However, no obvious facilitation was evident at any test potential (data not shown). These results demonstrate that the C-terminal modification of Gq allowed Galpha qz5 to couple to the alpha 2A-R, causing a reduction in IBa, although the inhibition was voltage-independent and smaller than that elicited by the tandems alpha 2A-R-Galpha o and alpha 2A-R-Galpha i or the wild type alpha 2A-R coupling to endogenous G-proteins.


View larger version (17K):
[in this window]
[in a new window]
 
Fig. 5.   The ability of the Galpha qz5 subunit to support G-protein modulation of CaV2.2 currents. a, example traces recorded in the presence and absence of clonidine from a cell expressing the alpha 2A-R w.t. and Galpha qz5. b, inhibition by clonidine in cells expressing the alpha 2A-R w.t. with the Galpha q w.t. subunit (n = 5, left) or the alpha 2A-R w.t. with the Galpha qz5 subunit (n = 9, right). , inhibition during P1; , inhibition during P2. c, facilitation (P2/P1 ratio) of currents in control () and after application of clonidine (black-square) for the same combinations of constructs as in b. All cells were pretreated with PTX. Statistical significance compared with Galpha q w.t., ***, p < 0.001, Student's t test.

Interaction between alpha 2A-R-Galpha o and Galpha qz5. It has been observed previously that chimeric receptor-Galpha constructs are able to activate not only the tethered Galpha subunit but also endogenous subunits of the Gi/o family (Burt et al., 1998). Accordingly, Galpha qz5 might be expected also to interact with, and to be activated by, the alpha 2A-R-Galpha o tandem used in this part of the study. We investigated this potential interaction by coexpressing the tandem alpha 2A-R-Galpha o with the Galpha qz5 subunit, and treating all cells with PTX.

The first observation was that the inhibition of IBa obtained when coexpressing alpha 2A-R-Galpha o with Galpha qz5 was significantly smaller than in cells expressing alpha 2A-R-Galpha o alone (Fig. 6a). Inhibition was 21.0 ± 12.4% in P1 (n = 16, p < 0.01, Fig. 6b). Interestingly, the presence of Galpha qz5 also almost abolished facilitation by the PP at all potentials examined (Fig. 6c). For example the P2/P1 facilitation ratio in clonidine was 1.24 ± 0.38 at 0 mV and 0.87 ± 0.11 at +10 mV (n = 11, both p < 0.01 compared with the much greater facilitation shown by the alpha 2A-R-Galpha o alone). As a corollary of this, no agonist-induced depolarizing shift of the I-V relationship for IBa was detected (data not shown). Furthermore, no slowing of the activation kinetics was evident during P1 (e.g., Fig. 6a). In summary, coexpression of Galpha qz5 with alpha 2A-R-Galpha o reduced the inhibition and reversed the P2/P1 facilitation observed upon activation of the alpha 2A-R-Galpha o alone.


View larger version (18K):
[in this window]
[in a new window]
 
Fig. 6.   The effect of Galpha qz5 is counteracted by a C terminal construct of phospholipase C-beta 1. a, example recordings from cells expressing both the tandem alpha 2A-R-Galpha o and the Galpha qz5 subunit without (left) and with (right) the additional presence of PLC-beta 1ct. The voltage protocol is that shown in Fig. 1. b, mean percentage inhibition by clonidine for alpha 2A-R-Galpha o alone (n = 18); alpha 2A-R-Galpha o and Galpha qz5 (n = 16); and alpha 2A-R-Galpha o, Galpha qz5, and PLC-beta 1ct (n = 6). Statistical significance, **, p < 0.01; *, p < 0.05 as indicated. c, voltage-dependence of facilitation ratio for coexpression of alpha 2A-R-Galpha o and Galpha qz5 (n = 11). Voltage protocol as in Fig. 2a. d, voltage-dependence of facilitation ratio for coexpression of alpha 2A-R-Galpha o, Galpha qz5, and PLC-beta 1ct (n = 6). Voltage protocol as in Fig. 2a. Statistical significance, *, p < 0.05, compared with the P2/P1 ratio in clonidine for alpha 2A-R-Galpha o, Galpha qz5 in the absence of PLC-beta 1ct (given in Fig. 6c).

Mechanism of Action of Galpha qz5. We addressed the possibility that the effects produced by Galpha qz5 on CaV2.2 channel modulation might be mediated by a signaling pathway downstream from Gq rather than directly by the Galpha qz5 subunit. It has been proposed that overexpression of any Galpha subunit could abolish calcium channel inhibition by sequestering Gbeta gamma subunits, which would therefore become unavailable for receptor activation (Jeong and Ikeda, 1999). However, this will depend on the balance between Galpha activation to form free Galpha -GTP and Gbeta gamma interaction with the Galpha -GDP species. In such a scenario, coexpression of Galpha qz5 could buffer the effect of the Gbeta gamma released upon activation of alpha 2A-R-Galpha o, in a similar way to transducin; as we have shown, however, Galpha qz5 is able to be activated. Once activated, it would then lead to stimulation of phospholipase C (Conklin et al., 1993), causing breakdown of phosphatidylinositol 4,5-bisphosphate (PIP2) into inositol 1,4,5-trisphosphate and diacylglycerol, the latter stimulating PKC. Activation of PKC has been reported to counter G-protein modulation of rat CaV2.2 (Zamponi et al., 1997; Hamid et al., 1999). However, elevation of PIP2 has also been shown to modulate CaV2.1, mimicking that by Gbeta gamma (Wu et al., 2002). To investigate whether the reduction in inhibition and loss of facilitation in our coexpression studies with Galpha qz5 were caused by a Gbeta gamma buffering effect or by a specific downstream effect of activated Galpha qz5 protein, we first chose to block the downstream action of activated Galpha qz5 by coexpressing the C-terminal peptide of phospholipase C-beta 1 (PLC-beta 1ct), which binds activated Galpha q and acts as a GTPase-activating protein (Kammermeier and Ikeda, 1999). Inhibition by clonidine in cells coexpressing alpha 2A-R-Galpha o and Galpha qz5 together with PLC-beta 1ct returned to levels comparable with when alpha 2A-R-Galpha o was expressed alone (Fig. 6b). Furthermore the P2/P1 facilitation ratio in the presence of clonidine was increased relative to that in the presence of alpha 2A-R-Galpha o and Galpha qz5 at all potentials between 0 and +20 mV, being 4.88 ± 2.48 at 0 mV and 2.25 ± 0.66 at +10 mV (Fig. 6d, n = 6, p < 0.05 relative to facilitation in clonidine for alpha 2A-R-Galpha o and Galpha qz5 alone at 0 and +10 mV).

Because PLC-beta 1ct only binds activated Gq species and was able to reverse the effect of Galpha qz5, this must occur via its GTP-bound form. We therefore examined the role of downstream effectors of Gq. We investigated the effect of activating PKC to mimic the presence of Galpha q as a signal transduction component, and simultaneously removed its presence as a potential Gbeta gamma buffering agent. We used PDBu, an activator of PKC, on cells expressing the alpha 2A-R-Galpha o fusion protein. After assessing the inhibition of CaV2.2 currents and the voltage-dependent facilitation elicited by clonidine alone, cells were perfused with PDBu (500 nM) in the presence of clonidine (Fig. 7, a and b). Within 5 min after the start of PDBu application, IBa partially recovered from inhibition by clonidine. During P1, inhibition by clonidine was reduced from 77.8 ± 6.1 to 56.1 ± 9.4% in the additional presence of PDBu (Fig. 7c, n = 7, p < 0.001). Application of PDBu also resulted in reduced current facilitation (Fig. 7d, n = 7). After application of PDBu and clonidine, the current during P1 showed a rapid activation phase, further evidence for the loss of voltage-dependent inhibition (e.g., Fig. 7a, traces). Both the loss of inhibition and the reduction of facilitation are similar to the effect of Galpha qz5. Application of PDBu (500 nM) in the absence of receptor activation did not cause any increase of CaV2.2 IBa, rather reducing it by 37 ± 9% after application for 3 min, with a loss of control facilitation (n = 6, data not shown).


View larger version (25K):
[in this window]
[in a new window]
 
Fig. 7.   Effect of an activator of PKC on clonidine-inhibited currents. a, superimposed example traces recorded from a cell expressing alpha 2A-R-Galpha o during application of clonidine and after coapplication of clonidine and 500 nM PDBu. The voltage protocol used was that depicted in Fig. 1. b, time course from the same cell as in a for the current measured in P1 () and P2 (open circle ). The letters correspond to the traces selected for a. c, percentage inhibition by clonidine before and during application of PDBu (n = 7), before (P1, ) and after (P2, ) the depolarizing PP. d, voltage-dependent facilitation for the same cells as in c in control (-), clonidine, and clonidine plus PDBu (statistical significances as indicated: *, p < 0.05; **, p < 0.01; NS, nonsignificant, paired t test).

In a second approach to examine the involvement of PKC in the effects of Galpha qz5, we observed that the PKC inhibitor GF109203X partially restored the voltage-dependence of G-protein modulation in the presence of Galpha qz5. After a 30-min preincubation with 1 µM GF 109203X, application of clonidine to cells expressing alpha 2A-R-Galpha o and Galpha qz5 produced a 54 ± 15% inhibition of IBa at 0 mV (n = 9), and the P2/P1 facilitation ratio approached that in the absence of Galpha qz5 [2.4 ± 0.5 (n = 9)]. These two pieces of data indicate that PKC activation is at least in part responsible for the effects of Galpha qz5.

    Discussion
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References

The Advantage of Using GPCR-G Protein Tandems. We sought to recreate proximity between a GPCR, the alpha 2AR, and a specific G-protein by using tandem constructs. Both the chimeric receptors alpha 2A-R-Galpha i and alpha 2A-R-Galpha o reconstituted N-type current inhibition, comparable with the alpha 2AR w.t. Similarly, it has been found that a tandem between the muscarinic m2 receptor and Galpha z was able to modulate GIRK channels by release of Gbeta gamma (Vorobiov et al., 2000). This is in contrast to their inability to activate downstream effectors via the Galpha moiety (Sautel and Milligan, 1998; Burt et al., 1998), presumably because the Galpha -subunits are not amplified and also because they are constrained. The conclusion of these results is that the release of Gbeta gamma from both the activated GPCR tandems is completely sufficient to produce typical voltage-dependent inhibition of N-type calcium channels. This is confirmed by the inability of the IE mutant of alpha 2A-R-Galpha o, which does not bind Gbeta gamma , to mediate inhibition of CaV2.2 by clonidine. Although tonic facilitation was seen with this mutant in the absence of agonist (Fig. 3c), this was no greater than for the nontandem alpha 2A-R (Fig. 2c), where inhibition by clonidine was observed (Fig. 1e).

It has been proposed that members of the Go subfamily are responsible for the voltage-dependent inhibition of calcium channels in sympathetic neurons, whereas Gi produced only a voltage-independent effect (Delmas et al., 1999). However, we did not find a clear correlation between the Galpha -subunit in the tandem and the voltage-dependence of the inhibition, although there was a slightly greater voltage-dependent effect with the alpha 2A-R-Galpha o fusion protein. This may relate to the endogenous Gbeta gamma dimers with which the Galpha subunits preferentially associate. Indeed, the kinetics and voltage-dependence of Gbeta gamma dissociation and reassociation are dependent on the nature of the Gbeta gamma dimers (Stephens et al., 1998).

Effects of Galpha q on G-Protein Modulation of Calcium Channels. The role of Gq in G-protein modulation of calcium currents remains unclear. It has been shown that Gq is not involved in modulation by the alpha 2A-R of the (largely N type) calcium currents in mouse sympathetic neurons (Haley et al., 2000). In the present study, expression of Galpha q produced negligible inhibition of N-type channels, consistent with its very low ability to couple to the alpha 2A-R (Chabre et al., 1994). In contrast, the chimeric counterpart, Galpha qz5, allowed significant inhibition of CaV2.2, indicating that substitution of the C terminus of Galpha z enhanced the coupling to the alpha 2A-R (Conklin et al., 1993). However, Galpha qz5 showed a reduced ability to inhibit IBa compared with Gi/o. The inhibition also showed a lack of voltage-dependence; together, these results suggested that Gqz5 acts via a different or modified signaling mechanism compared with Gi/o. A similar voltage-independent inhibition of Ca2+ channels by the Gq-coupled muscarinic m1 receptor was shown to involve both the Galpha q and Gbeta gamma subunits (Kammermeier et al., 2000). Furthermore, the voltage-independent inhibition was converted into voltage-dependent inhibition by sequestering activated Galpha q (Kammermeier and Ikeda, 1999).

In the present study, coexpression of Galpha qz5 with alpha 2A-R-Galpha o caused first a reduction of clonidine-induced inhibition of CaV2.2 and second a loss of voltage-dependent facilitation. This action of Galpha qz5 could result from a number of mechanisms: 1) Gbeta gamma buffering, as suggested for Galpha q (Jeong and Ikeda, 1999), or 2) Galpha qz5 might interact with, and be activated by, the alpha 2A-R-Galpha o tandem. It has been observed previously that chimeric receptor-Galpha constructs are able to activate not only the tethered Galpha subunit but also endogenous subunits of the Gi/o family (Burt et al., 1998). In the case of Galpha qz5 this would result in downstream activation of phospholipase C, resulting in elevation of inositol 1,4,5-trisphosphate and diacylglycerol and concomitant reduction of PIP2. One potential downstream pathway would be PKC activation and subsequent phosphorylation of either the calcium channel or the alpha 2A-R to suppress G-protein modulation. Another potential downstream pathway would be via reduction of PIP2, because elevation of PIP2 mimics and may play an essential role in G-protein modulation (Wu et al., 2002).

We have addressed these possibilities in turn. If the mechanism were Gbeta gamma sequestration, Galpha qz5 should act identically to Galpha t. However Galpha t reduced inhibition of CaV2.2 via alpha 2A-R-Galpha o from 75 to 43% but did not abolish facilitation in the presence of clonidine (Fig. 3a, traces). In contrast, Galpha qz5 reduced inhibition by clonidine to 36% but completely abolished facilitation (Fig. 5a, traces). Furthermore, in cells coexpressing alpha 2A-R-Galpha o and Galpha qz5, it was possible to restore typical Go-mediated facilitation by enhancing the GTPase activity of activated Galpha qz5 with PLC-beta 1ct. This suggests that the effect of Galpha qz5 is downstream from its activation.

Two pieces of evidence indicate that PKC activation is involved in the response to Galpha qz5, although it may not represent the entire story. Firstly, application of a PKC agonist to cells expressing alpha 2A-R-Galpha o mimicked the effects of Galpha qz5, resulting in reduced inhibition by clonidine and loss of PP facilitation. Secondly, in cells coexpressing alpha 2A-R-Galpha o and Galpha qz5, Go-mediated inhibition and facilitation were restored with a PKC inhibitor. Taken together, these results suggest that activation of the PLC-beta signaling pathway by the alpha 2A-R coupling to Gqz5 can oppose G-protein-mediated inhibition of CaV2.2.

Potential Targets for PKC Phosphorylation. PKC-mediated phosphorylation might occur at several sites, either separately or in combination. PKC activation has been shown to cause phosphorylation-dependent desensitization of the alpha 2A-R in COS-7 and Chinese hamster ovary cells (Liang et al., 1998). It is possible that this process may play a role in the effect of Galpha qz5, although it is unclear how this could result in a selective loss of facilitation while substantial clonidine-mediated inhibition remains. Alternatively, PKC could phosphorylate one or more calcium channel subunits, thus rendering the channel less responsive to G-protein mediated inhibition and abolishing facilitation. There are a number of possible mechanisms by which this might occur. Phosphorylation of CaV2.2 or an accessory beta  subunit may result in the loss of its ability to be modulated by Gbeta gamma . Residues in the I-II linker of rat CaV2.2 have been proposed to be a target of phosphorylation by PKC and to be responsible for PKC antagonism of G-protein modulation (Zamponi et al., 1997). Evidence has been presented recently that this process involves binding of Galpha q and PKC to the C terminus of CaV2.2 (Simen et al., 2001). Direct activation of PKC has been shown to counteract inhibition of N-type calcium channels by norepinephrine (Shapiro et al., 1996). Subsequently, the importance was examined of phosphorylation sites on the I-II linker of rat CaV2.2, including Thr422 and Ser425, in the modulation by PKC (Zamponi et al., 1997). An increase in calcium current was observed when mimicking channel phosphorylation on either of these residues by mutation to Glu, and a reduction of G-protein modulation by somatostatin when Thr422 was mutated to Glu (Hamid et al., 1999). However, this effect was subsequently observed only with Gbeta 1 and not with other Gbeta subunits, calling into question its general relevance (Cooper et al., 2000). Indeed, we have shown that G-protein modulation of CaV2.2 is not dependent on the presence of the I-II linker of a modulatable calcium channel, whereas the N terminus is essential (Canti et al., 1999).

Although the rabbit CaV2.2 used in the present study shows very high overall sequence conservation in the I-II linker, and retains Ser425, there is Ala at position 422, thus ruling out the role of phosphorylation of this residue in removing G-protein modulation. In addition, Ser425 is not an optimal consensus PKC phosphorylation motif (AAAKKSRSD). Furthermore, we did not observe any increase of N-type IBa upon application of PDBu in the absence of G-protein modulation. This would agree with results in superior cervical ganglion neurons, where the only effect of PKC activation was antagonism of G-protein inhibition (Barrett and Rittenhouse, 2000).

The mechanism of the reduction of G-protein modulation and loss of P2/P1 facilitation that is characteristic of coexpression of Galpha qz5 thus seems to involve its activation, and at least in part involves downstream activation of PKC, but the main target site(s) for phosphorylation may not be the calcium channel alpha 1 subunit. Facilitation involves the unbinding of Gbeta gamma subunits from the channel during the depolarizing PP (Stephens et al., 1998); this requires the functional interaction of CaVbeta subunits (Canti et al., 2000, 2001; Meir et al., 2000). In the absence of coexpressed CaVbeta subunit, we observed previously that activation of the D2 dopamine receptor produced only a small voltage-independent inhibition of CaV2.2 calcium channels, whereas in the presence of CaVbeta subunits, the inhibition was much larger and voltage-dependent (Meir et al., 2000). It is therefore possible that phosphorylation of the CaVbeta subunit might mediate the loss of facilitation resulting from Galpha qz5 coexpression. Indeed, another CaVbeta subunit, beta 2a, is phosphorylated stoichiometrically by PKC (Puri et al., 1997). We will examine in a future study whether phosphorylation of CaVbeta subunits by PKC is responsible for the effects of Galpha qz5.

    Acknowledgments

We are grateful to N. Balaguero, W. S. Pratt, M. Nieto-Rostro, and K. Chaggar for technical assistance, to Drs. K. M. Page and N. S. Berrow for molecular biology expertise, and to A. Meir for helpful discussion. We thank the following for gifts of cDNA: Dr. L. E. Limbird (Vanderbilt University, Nashville, TN) (alpha 2A-R); Dr/B. Conklin (J. David Gladstone Institutes, San Francisco, CA) (Galpha q and Galpha qz5); and Dr. S. Ikeda (National Institutes of Health, Bethesda, MD) (PLC-beta 1ct).

    Footnotes

Received September 11, 2002; Accepted January 14, 2003

Address correspondence to: A.C. Dolphin, Department of Pharmacology, Medawar Building, University College London, Gower Street, London WC1E 6BT, UK. E-mail: a.dolphin{at}ucl.ac.uk

    Abbreviations

GPCR, G-protein-coupled receptor; alpha 2A-R, alpha 2A-adrenergic receptor; PTX, pertussis toxin; GIRK, G-protein-coupled inward rectifier K channel; GFP, green fluorescent protein; w.t., wild type; RS-79948-197, [8aR,12aS,13aS]5,6,8a,9,10,11,12,12a,13,13a-decahydro-12-ethanesulfonyl-3-methoxy-6H-isoquino[2,1-g]-[1,6]naphthyridine hydrochloride); GTPgamma S, guanosine 5'-O-(3-thio)triphosphate; HA, hemagglutinin; PAGE, polyacrylamide gel electrophoresis; PVDF, polyvinylidene fluoride; TTBS, Tween 20/Tris buffered saline; PDBu, phorbol dibutyrate; GF 109203X, bisindolylmaleimide I; PKC, protein kinase C; PLC-beta 1ct, phospholipase C-beta 1 C terminus; PP, prepulse; Galpha t, Galpha -transducin; PIP2, phosphatidylinositol 4,5-bisphosphate; IE, Ile19Ala, Glu20Ala.

    References
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References


0026-895X/03/6304-832-843$3.00
Mol Pharmacol, 63:832-843, 2003
Copyright © 2003 by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
Physiol. Rev.Home page
S. Dai, D. D. Hall, and J. W. Hell
Supramolecular Assemblies and Localized Regulation of Voltage-Gated Ion Channels
Physiol Rev, April 1, 2009; 89(2): 411 - 452.
[Abstract] [Full Text] [PDF]


Home page
Pharmacol. Rev.Home page
H. W. Tedford and G. W. Zamponi
Direct G Protein Modulation of Cav2 Calcium Channels
Pharmacol. Rev., December 1, 2006; 58(4): 837 - 862.
[Abstract] [Full Text] [PDF]


Home page
Pharmacol. Rev.Home page
A. C. Dolphin
G Protein Modulation of Voltage-Gated Calcium Channels
Pharmacol. Rev., December 1, 2003; 55(4): 607 - 627.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bertaso, F.
Right arrow Articles by Dolphin, A. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bertaso, F.
Right arrow Articles by Dolphin, A. C.


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2003 by the American Society for Pharmacology and Experimental Therapeutics